GSK stock reacts to mRNA flu vaccine progress as earnings guidance holds

GSK stock is navigating mRNA flu vaccine developments and a mixed sales picture, with reaffirmed 2026 guidance and a cautious consensus view on growth and valuation.

GSK stock (ISIN GB0009252882) is trading around 50.25 USD on the New York Stock Exchange as of September 1, 2026, after an early-session decline of about 1.12 percent compared with the prior close, according to data from a market overview compiled by Yahoo Finance.

mRNA flu vaccine moves into Phase 3

On September 2, 2026, GSK announced that it will advance its mRNA seasonal flu vaccine candidate FLUm3HA.b-3NA into Phase 3 clinical development following positive Phase 2 data in adults, according to a company press release.

The Phase 2 trial enrolled 971 adults and showed that the candidate generated higher immune responses than standard-dose and high-dose inactivated flu vaccines in younger and older adults respectively, based on results presented on September 1, 2026, at the Options XIII influenza conference as summarized in a sector report on Biomed Nexus.

Sector commentary from CMoney notes that GSK is aiming to use FLUm3HA.b-3NA to compete with established mRNA players in seasonal flu, with the Phase 3 start planned for September 2026 and the Phase 2 data indicating a meaningful step forward in protective potential compared with current non-mRNA vaccines.

Earnings, guidance and consensus view

Beyond the vaccine news, investors are watching how GSK balances new growth drivers with its core business performance. A recent analysis by Zacks on September 1, 2026, highlights that GSK’s second-quarter 2026 core sales rose 5 percent while core operating profit increased 7 percent, underscoring that underlying operating performance remains solid despite share price volatility.

The same Zacks note indicates that GSK reaffirmed its 2026 guidance alongside the second-quarter results, signaling management confidence in achieving its targets even as some legacy segments face pressure. In the General Medicines segment, sales declined 7 percent in the first half of 2026 due to ongoing generic erosion and competition in mature respiratory and other established products, illustrating the drag that older portfolios can exert on headline growth.

For investors focusing on valuation, Zacks reports that GSK stock trades at a forward 12-month price/earnings ratio of 10.12, significantly below the industry’s 18.69, while the Zacks Consensus Estimate for 2026 earnings per share has edged down from 4.84 to 4.80 USD over the past 30 days and the 2027 estimate from 5.15 to 5.05 USD, pointing to slightly softer expectations for medium-term profit growth.

Analyst ratings and DACH relevance

Analyst sentiment around GSK remains cautious but not outright negative. According to a MarketBeat overview dated September 2, 2026, GSK carries an average rating of Hold and a consensus price target of 2,048.57 GBX, suggesting limited upside in the view of covering analysts at current levels.

The same MarketBeat alert notes that Deutsche Bank Aktiengesellschaft has recently reaffirmed its Hold rating on GSK’s London listing, providing a concrete DACH-region anchor for German-speaking investors following the stock and reinforcing the picture of a company seen as fundamentally sound but not without execution and growth risks.

Vaccine portfolio and product focus

Alongside its mRNA ambitions, GSK’s broader vaccines portfolio remains a central earnings driver. The Zacks analysis from September 1, 2026, emphasizes that growth in newer vaccines and specialty medicines continues to offset pressures in General Medicines, with steady sales and profit improvement expected over the coming years if execution stays on track.

For retail investors, the shift toward innovative platforms such as mRNA in seasonal flu adds another layer of potential upside to the existing vaccine franchise. The planned Phase 3 trial of FLUm3HA.b-3NA, with Phase 2 data in 971 adults showing higher immune responses than licensed comparators, illustrates how GSK is trying to position itself competitively in a field currently led by mRNA specialists.

Stock level and market indicators

At a share price of 50.25 USD as of the close on September 1, 2026, GSK stock is modestly below the recent level of 50.66 USD recorded on August 31, 2026, according to a sector overview on Biomed Nexus, corresponding to a move of around 0.8 percent over that two-day period.

A separate valuation-focused article from GuruFocus on September 1, 2026, notes that GSK’s share price of 50.25 USD stands about 10.0 percent above its GF Value of 45.67 USD, suggesting a fairly valued but slightly stretched level based on that intrinsic value model. That comparison between the current market price and an estimated intrinsic value offers a numerical perspective on the risk-reward balance facing investors who are considering new positions or holding existing shares.

GSK stock at a glance

• Company: GSK plc
• ISIN: GB0009252882
• Ticker: GSK
• Trading venue: NYSE (primary listing), London Stock Exchange; ADR traded in USD
• Price (as of September 1, 2026, 18:25): 50.25 USD
• Market capitalization: Based on recent data, GSK’s valuation is assessed around the GF Value model, with the current share price of 50.25 USD standing 10.0 percent above an intrinsic value estimate of 45.67 USD as of September 1, 2026.
• Sector / Industry: Pharmaceuticals / Biotechnology
• Index membership: FTSE 100